Programmable by design.
Every candidate begins with a defined functional specification, and the design is built around what the biology reveals.
Programmable therapeutic modalities · AI-enabled development
Biology is programmable.Precision is achievable.Speed is possible.
ARIA Therapeutics is a biotechnology company developing a new class of programmable therapeutic modalities, designed to reach targets that conventional medicines cannot and to go beyond inhibition.
By bringing selective recognition, coordinated function, and controlled activity together in a therapeutic construct, and learning from every experiment through an AI-enabled design loop, we aim to make therapeutic function something that can be engineered, not only discovered.
The opportunity 01
Different biological challenges demand different therapeutic capabilities.
Some therapeutic challenges require more than a new candidate within an established modality. They require different ways to recognise biological signals, coordinate functions, and control activity.
Conventional small molecules and biologics work best when a target offers a well-defined pocket or active site to occupy. Many disease-driving proteins offer neither, including regulatory and scaffolding proteins and targets that closely resemble healthy counterparts, so they have remained difficult to address with conventional approaches.
Even when a target is reachable, a single mechanism is often not enough. Efficacy may depend on sustained target engagement. Resistance can emerge. Selectivity between diseased and healthy cells remains difficult to achieve. And blocking one activity may leave compensatory pathways intact. ARIA is developing programmable therapeutic modalities to address these limitations, pursuing targets previously considered undruggable and designing therapeutic activity shaped by disease context.
Our approach 02
Engineering therapeutic function.
Our approach connects computational design, physical synthesis, and experimental validation in a closed learning loop. Each result feeds back into design, refining the composition, architecture, and function of the next generation of constructs.
Our AI-enabled learning loop supports this iterative engineering cycle, while physical production and experimental testing remain integral to development.
Precise by construction.
Efficacy and selectivity are design constraints from the start. Recognition, coordinated function, and control of activity are each tested experimentally.
Scalable by automation.
Scalability works in two ways. Accumulated experimental evidence makes AI-enabled design more adaptable across disease contexts, and cell-free production is central to increasing production scale and speed, extending development beyond a single indication.
Our purpose 03
Programming therapeutic function. Expanding therapeutic possibility.
Bringing programmability, precision, and speed into drug development.
Our ambition is to build therapeutic modalities that overcome the bottlenecks of conventional approaches and adapt to biological requirements, instead of producing more candidates within existing classes.
We build with patients in mind, for whom the timeline is finite, and for whom speed and precision matter.
Collaboration 04
Shape the next stage of programmable therapeutics.
Explore how programmable modalities open new ground for AI-enabled design, efficacy, and development.
We welcome discussions with biopharma, manufacturing, and translational partners, including advisory participation in funded programmes and longer-term development and manufacturing collaborations.
Contact 05
Start a conversation.
For scientific collaboration, partnership, investment, and operating enquiries, contact us directly.
hello@aria-tx.com